

Statement



To whom it may concern:

Product name: **One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)**

We, Getein Biotech, Inc., stated that as of October 19th, 2022, in silico analysis and/or experimental analysis of the recombinant SARS-CoV-2 variants N protein has proved that the following SARS-CoV-2 variants have no impact on the test performance of the above products.

No.	Virus/Lineage	No.	Virus/Lineage
1	SARS-CoV-2	19	B.1.621
2	B.1.1.7	20	B.1.526
3	B.1.351 / B.1.429 / B.1.427	21	BA.2/ BA.3/ BA.5/ XE/ BA.2.11/ BA.2.12.1/ BA.2.13
4	P.1	22	BA.4
5	B.1.617/XD	23	B.2.9.1
6	B.1.617.1	24	C.63.3
7	B.1.617.2	25	AY.42
8	B.1.617.3	26	BA.2.75
9	P.2	27	BE.3
10	A.23.1 with E484K-1	28	BE.1
11	A.23.1 with E484K-2	29	BA.5.2.1.7 (BF.7)
12	B.1.1.7 with E484K	30	BQ.1.1
13	B.1.525 (previously designated UK1188)	31	BJ.1
14	B.1.1.318	32	BS.1
15	P.3	33	BA.2.10
16	AV.1	34	BA.2.75.2
17	B.1.1.529 (Omicron)/BA.1/BA1.1/XF	35	BA.4.6
18	C.37	36	BA.5.2.1

After that, we will track the updates of SARS-CoV-2 variants on the following websites and databases on a **weekly basis**, conduct in silico analysis and test performance evaluation if there are new variants.

Database:

WHO website:

<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>

GISAID website:

<https://www.gisaid.org/hcov19-variants/>

UK website:

<https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data>

Company: Getein Biotech, Inc. [Stamp]

October 19th, 2022